{'fraction_non_alphanumeric': 0.03150134048257373, 'fraction_numerical': 0.00804289544235925, 'mean_word_length': 5.195020746887967, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Analysis of Association Between Genetic Heterogeneity of Interferon Beta Receptor Promoter and Therapeutic Response to Interferon-beta in a Patient with Multiple Sclerosis


 Multiple sclerosis (MS) is an autoimmune disease characterized by inflammatory neuronal damages and consequent disabilities. Episodic relapses of the disease could be decreased by the interferon-beta (IFN-β) therapy in most MS patients. However, the drug response’s efficiency is variable among patients, and the precise mechanism of action of the IFN-β is not clear. This study aimed to investigate the interferon beta-receptor (IFNAR) promoter polymorphisms on response to interferon beta in MS patients. Patients were divided into either responding (n = 57) or non-responding (n = 43) groups according to interferon beta treatment and Expanded Disability Status Scale score. The Sanger sequencing method is used for genotyping. Here, we found a significant association between 65 SNP in responders and non-responders to interferon beta (p-value < 0.05). The results also showed a significant difference between the two groups of responders and non-responders to the treatment in the presence or absence of insertion before GT repeat dinucleotide microsatellite (p-value < 0.02). The present study’s obtained results suggested the genetic heterogeneity in the promoter region of IFNAR can affect response to IFN-β. However, more studies with a larger sample size are needed to demonstrate this relationship further.